LifeMatrix Technologies AG is a pioneering startup based in Zürich, specializing in groundbreaking bio-engineering technology aimed at developing human replacement tissues for cardiovascular treatments. Our cutting-edge methods are paving the way for next-generation implants, designed to improve patient outcomes in addressing cardiovascular diseases.
As a pre-revenue company spun out of the Institute for Regenerative Medicine at the University of Zurich, LifeMatrix is at the forefront of transforming cardiac healthcare. Our team comprises world-renowned experts in cardiovascular tissue engineering paired with seasoned entrepreneurs skilled in the development of medical biomimetic devices.
LifeMatrix has garnered multiple prestigious awards, signifying industry recognition for our innovation and potential impact. Noteworthy highlights include:
| Year | Award | Description |
|---|---|---|
| 2023 | Innosuisse Start-up Innovation Project | Recognition by Swiss Innovation Agency for our innovative solutions. |
| 2023 | Top Cardiovascular Medtech Startup | Awarded by Med Tech Outlook, recognizing our innovative advancements. |
| 2022 | Pionierpreis | Significant innovation prize for young companies in Switzerland. |
Our technology focuses on creating human cell-derived, off-the-shelf tissue-engineered implants that integrate seamlessly into the body. These implants not only mimic natural tissue but also possess the unique ability to grow and regenerate alongside the patients they serve, thereby enhancing long-term treatment efficacy.
With over 20 years of dedicated research and more than 100 peer-reviewed publications, LifeMatrix has established a solid foundation of safety and efficacy through extensive preclinical studies. Our commitment to innovation in the biomimetic field continues to drive us forward in translating these advancements into clinical practice.
Join us on our mission to revolutionize cardiovascular healthcare with state-of-the-art tissue engineering solutions.